Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Naltrexone

These are related to the Naltrexone news, in which you can learn about the latest trends in Naltrexone and related information industry, to help you better understand and expand Naltrexone market.
  • Drug Patent & Exclusivity Expiration Report - Week of March 24 2025

    Drug Patent & Exclusivity Expiration Report - Week of March 24 2025

    2025-03-24

    This week, there are 10 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - NALPROPION PHARMACEUTICALS LLC's CONTRAVE, containing active ingredient BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - WYETH PHARMACEUTICALS LLC's PROTONIX, containing active ingredient PANTOPRAZOLE SODIUM - PURDUE PHARMA LP's OXYCONTIN, containing active ingredient OXYCODONE HYDROCHLORIDE - UCB INC's FINTEPLA, containing active ingredient FENFLURAMINE HYDROCHLORIDE - BRISTOL MYERS SQUIBB CO's ZEPOSIA, containing active ingredient OZANIMOD HYDROCHLORIDE - VERITY PHARMACEUTICALS INC's TLANDO, containing active ingredient TESTOSTERONE UNDECANOATE - NOVO NORDISK INC's OZEMPIC, containing active ingredient SEMAGLUTIDE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - VIIV HEALTHCARE CO's VOCABRIA, containing active ingredient CABOTEGRAVIR SODIUM Read More